Fig. 5From: Clinical relevance between sodium-glucose co-transporter 2 inhibitors and lipid profiles in Asian patients with type 2 diabetes mellitus: a systematic review with a meta-analysis of randomized controlled trialsRelationship between SGLT2is and changes in HDL-C. Abbreviations: CANA, canagliflozin; EMPA, empagliflozin; IPRA, ipragliflozin; LUSEO, luseogliflozin; TOFO, tofogliflozin; SGLT2i, sodium-glucose co-transporter 2 inhibitor; HDL-C, high-density lipoprotein cholesterol; CI, confidence interval; SD, standard deviation.Back to article page